Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07215234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07215234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 9, 2025
Completion date
July 22, 2032
Enrollment
104 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy